对比增强乳腺X线摄影中的强化类型与恶性关联
本研究回顾性分析单中心2015年12月至2019年12月371例诊断性对比增强乳腺X线摄影,评估重组图像上强化类型与恶性的关联。强化对恶性的敏感度为95%、特异度为67%、阳性预测值为55%、阴性预测值为97%。肿块强化最常见于恶性,尤其当低能图像有相应发现时恶性率为59%,无低能发现时为26%(P < .001)。
要点
- 重组图像上强化对恶性敏感度95%、特异度67%、阳性预测值55%、阴性预测值97%。
- 肿块强化占所有恶性的71%,伴低能图像发现时阳性预测值为63%。
- 无低能图像发现的点状、非肿块和肿块强化的阳性预测值分别为6%、24%和38%。
核心结论
- 重组图像上的肿块强化最常与恶性相关,尤其当低能图像有相应发现时;无低能图像发现时强化类型更可能为良性,但因与恶性关联高仍应怀疑。
研究设计与样本
- 回顾性分析单学术机构2015年12月至2019年12月所有诊断性对比增强乳腺X线摄影,共371例371名女性(平均年龄54岁±11[SD]),由三名乳腺影像放射科医生独立阅片,采用BI-RADS乳腺X线摄影和MRI词典,结局由病理分析或1年影像或临床随访确定。
诊断标准与关键数值
- 强化对恶性的敏感度为95%(104/109,95%CI:90,98),特异度为67%(176/262,95%CI:61,73),阳性预测值为55%(104/190,95%CI:47,62),阴性预测值为97%(176/181,95%CI:94,99)。伴低能图像发现时恶性率为59%,无低能图像发现时为26%(P < .001)。肿块强化占所有恶性的71%(99/140),伴低能图像发现时阳性预测值为63%。无低能图像发现的点状、非肿块和肿块强化阳性预测值分别为6%、24%和38%。背景实质强化和密度与强化类型均无关联(P = .19和P = .28)。
临床应用与阅片要点
- 阅片时应结合重组图像强化类型与低能图像发现综合判断:伴低能图像发现的肿块强化阳性预测值为63%,无低能图像发现的点状、非肿块和肿块强化阳性预测值分别为6%、24%和38%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Despite the increasing use of contrast-enhanced mammography (CEM), there are limited data on the evaluation of findings on recombined images and the association with malignancy. Purpose To determine the rates of malignancy of enhancement findings on CEM images in the presence or absence of low-energy findings using the Breast Imaging Reporting and Data System (BI-RADS) lexicon developed for mammography and MRI. Materials and Methods All diagnostic CEM examinations performed at one academic institution between December 2015 and December 2019 had low-energy and recombined images retrospectively. Data were independently reviewed by three breast imaging radiologists with 5-25 years of experience using the BI-RADS mammography and MRI lexicon. Outcome was determined with pathologic analysis or 1-year imaging or clinical follow-up. The χ2 and Fisher exact tests were used for analysis. Results A total of 371 diagnostic CEM studies were performed in 371 women (mean age, 54 years ± 11[SD]). Sensitivity, specificity, positive predictive value (PPV), and negative predictive value of enhancement on CEM images was 95% (104 of 109 [95% CI: 90, 98]), 67% (176 of 262 [95% CI: 61, 73]), 55% (104 of 190 [95% CI: 47, 62]), and 97% (176 of 181 [95% CI: 94, 99]), respectively. Among 190 CEM studies with enhancing findings, enhancing lesions were more likely to be malignant when associated with low-energy findings (26% vs 59%, P < .001). Among enhancement types, mass enhancement composed 71% (99 of 140) of all malignancies with PPV of 63% when associated with low-energy findings. Foci, non-mass enhancement, and mass enhancement without low-energy findings had PPV of 6%, 24%, and 38%, respectively. Neither background parenchymal enhancement nor density was associated with enhancement type (P = .19 and P = .28, respectively). Conclusion Mass enhancement on recombined images using CEM was most commonly associated with malignancy, especially when associated with low-energy findings. Enhancement types were more likely to be benign when not associated with low-energy findings; however, they should still be viewed with suspicion, given the high association with malignancy. © RSNA, 2022 Online supplemental material is available for this article.
引用
- Kim, Mehta, Brook, et al. Enhancement Type at Contrast-enhanced Mammography and Association with Malignancy. Radiology. 2022. PMID: 35819328. doi:10.1148/radiol.210966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。